Universitat Autònoma

Featured in: Favicon

nature.com Favicon

frontiersin.org Favicon

jamanetwork.com Favicon

thelancet.com Favicon

neurology.org Favicon

ashpublications.org Favicon

jacionline.org Favicon

internationaljournalofcardiology.com + 4 more

Articles

Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial

Jul 26, 2023 | thelancet.com | Patricia Pozo-Rosich |Universitat Autònoma |Jessica Ailani |Messoud Ashina

Summary In this study, we aimed to evaluate the efficacy, safety, and tolerability of atogepant for the preventive treatment of chronic migraine. We did this randomised, double-blind, placebo-controlled, phase 3 trial at 142 clinical research sites across the USA, the UK, Canada, China, Czech Republic, Denmark, France, Germany, Italy, Japan, South Korea, Poland, Russia, Spain, Sweden, and Taiwan.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →